Reference pricing may shift the mix of drugs dispensed from those offering the highest rebates to pharmacy benefit managers to those offering the lowest prices to employers and employees, according to a new study published Wednesday.
Reference-based pricing benefit design for prescription drugs led to both increased use of lower-cost therapies within each therapeutic class and a drop in the prices paid by employers and cost sharing borne by employees, according to a new study published Wednesday in JAMA Network Open.
The technique may shift the mix of drugs dispensed from those offering the highest rebates to pharmacy benefit managers to those offering the lowest prices to employers and employees, according to the authors.
The use of reference-based pricing has been limited in the United States; it is more widely used in Euope. A study published last year in The American Journal of Managed Care® found that few employers have inplemented the strategy, under which patients are responsible for the cost of a drug or medical service that goes above a specified price.
The economic evaluation examined 3.3 million drug insurance claims of employees of Catholic organizations who purchased health insurance through the Reta Trust, using a random sample of employees of public sector organizations who purchased insurance through the California Public Employees’ Retirement System (CalPERS) as a comparison group.
The Reta Trust implemented reference pricing in July 2013; CalPERS did not adopt reference pricing during the study period, which ran from July 1, 2010, to December 31, 2017. Data analysis was performed from January 1, 2019, to September 1, 2019.
During the study period, 1.2 million prescriptions were submitted by 34,319 individuals covered by Reta Trust; in the CalPERS group, 2.1 million prescriptions were submitted by 738,159 individuals.
In the first 2.5 years after implementation of reference pricing, the percentage of prescriptions made for the low-priced drug within each therapeutic class increased by 5.1 percentage points (95% CI, 1.8-8.4 percentage points), and patient cost sharing increased by 10.3% (95% CI, −1.6% to −23.6%). The difference was not statistically significant. Meanwhile, the prices paid decreased by 19.1% (95% CI, −30.2% to −6.2%) for Reta Trust patients compared with CalPERS patients.
During the subsequent 2-year postimplementation period, the percentage of prescriptions given for the low-priced drug increased an additional 6.2 percentage points (95% CI, 2.3-10.1 percentage points) and patient cost sharing decreased by 21.3% (95% CI, −31.2% to −9.9%). In addition, prices paid increased by 7.2% (95% CI, −12.6% to 31.4%) and were also not statistically significant.
Relative to the change experienced by the CalPERS patients, the share of prescriptions for lower-priced drugs increased by 6.3 percentage points (8.9% relative increase), the mean prescription drug price decreased by $9.5 (12.1% relative decrease), and the mean patient cost sharing decreased by $1.8 (4.3% relative decrease).
Reference
Robinson JC, Whaley C, Brown TT, Dhruva SS. Physician and patient adjustment to reference pricing for drugs [published online February 5, 2020]. JAMA Network Open. doi: 10.1001/jamanetworkopen.2019.20544.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.